3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Dermatologic
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Newly Diagnosed Glioblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, Large B-Cell, Diffuse
1
Locally Advanced or Metastatic Solid Tumors
1
Glioma
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Temozolomide
32
Radiotherapy
11
Bevacizumab
10
Surgical Procedures, Operative
7
IL13-PE38
7
TIC10 compound
6
Lomustine
6
Carboplatin
6
Radiation
5
Chlorotoxin
5
vorasidenib
4
trametinib
4
dabrafenib
4
Valacyclovir
4
OKN 007
4
Flucytosine
4
Dianhydrogalactitol
4
Cyclophosphamide
4
vocimagene amiretrorepvec
3
abemaciclib
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
CLR1404
3
trans-sodium crocetinate
2
pembrolizumab
2
olutasidenib
2
marizomib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioma
×
efineptakin alfa
×
Clear all
NCT04289155
2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available